The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease
Open accessAbstract
Summary: Background: Fibrotic stricture is a common complication of Crohn's disease (CD) affecting approximately half of all patients. No specific anti‐fibrotic therapies are available; however, several therapies are currently under evaluation. Drug development for the indication of stricturing CD is hampered by a lack of standardised definitions, diagnostic modalities, clinical trial eligibility criteria, endpoints and treatment targets in stricturing CD. Aim: To standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Chron's disease. Methods: An interdisciplinary expert panel consisting of 15 gastroenterologists and radiologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 109 candidate items derived from systematic review and expert opinion focusing on small intestinal strictures were anonymously rated as inappropriate, uncertain or appropriate. Survey results were discussed as a group before a second and third round of voting. Results: Fibrotic strictures are defined by the combination of luminal narrowing, wall thickening and pre‐stenotic dilation. Definitions of anastomotic (at site of prior intestinal resection with anastomosis) and naïve small bowel strictures were similar; however, there was uncertainty regarding wall thickness in anastomotic strictures. Magnetic resonance imaging is considered the optimal technique to define fibrotic strictures and assess response to therapy. Symptomatic strictures are defined by abdominal distension, cramping, dietary restrictions, nausea, vomiting, abdominal pain and post‐prandial abdominal pain. Need for intervention (endoscopic balloon dilation or surgery) within 24‐48 weeks is considered the appropriate endpoint in pharmacological trials. Conclusions: Consensus criteria for diagnosis and response to therapy in stricturing Crohn's disease should inform both clinical practice and trial design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Multiple anti-fibrotic compounds are currently under evaluation for the treatment of liver, skin, kidney, heart and lung disease,(9) with 2 agents approved for use in patients with lung fibrosis (pirfenidone and nintedanib).(10,11) In contrast, there have been no trials of antifibrotics in inflammatory bowel diseases…”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
(2001) · Defense Technical Information Center (DTIC) · Cited by 2,158
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationDaperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Self-citationLouis, E., Collard, A., Oger, A. F., Degroote, E., El Yafi, F. A. N., & Belaiche, J. (2001) · Gut · doi:10.1136/gut.49.6.777 · Cited by 1,005
Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R., & Loftus, E. V. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.070 · Cited by 792
Self-citationClinical Patterns in Crohn's Disease: A Statistical Study of 615 Cases
Farmer, R. G., Hawk, W. A., & Turnbull, R. B. (1975) · Gastroenterology · doi:10.1016/s0016-5085(75)80270-8 · Cited by 699
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Panés, J., Bouzas, R., Chaparro, M., García-Sánchez, V., Gisbert, J. P., Martínez de Guereñu, B., Mendoza, J. L., Paredes, J. M., Quiroga, S., Ripollés, T., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04710.x · Cited by 659
Self-citation
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Self-citationRevisiting fibrosis in inflammatory bowel disease: the gut thickens
D’Alessio, S., Ungaro, F., Noviello, D., Lovisa, S., Peyrin-Biroulet, L., & Danese, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00543-0 · Cited by 253
Kucharzik, T., Tielbeek, J., Carter, D., Taylor, S. A., Tolan, D., Wilkens, R., Bryant, R. V., Hoeffel, C., De Kock, I., Maaser, C., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab180 · Cited by 149
Self-citationZhao, S., Dejanovic, D., Yao, P., Bhilocha, S., Sadler, T., Schirbel, A., West, G., Doyon, G., Lopez, R., Mao, R., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0259-9 · Cited by 59
Self-citationThe evolution of IBD perceived engagement and care needs across the life-cycle: a scoping review
Volpato, E., Bosio, C., Previtali, E., Leone, S., Armuzzi, A., Pagnini, F., & Graffigna, G. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01850-1 · Cited by 34
Metadata
- Authors
- Rieder, F., Bettenworth, D., Ma, C., Parker, C. E., Williamson, L. A., Nelson, S. A., van Assche, G., Di Sabatino, A., Bouhnik, Y., Stidham, R. W., Dignass, A., Rogler, G., Taylor, S. A., Stoker, J., Rimola, J., Baker, M. E., Fletcher, J. G., Panes, J., Sandborn, W. J., Feagan, B. G., & Jairath, V.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2018-06-19
- Volume
- 48
- Issue
- 3
- Pages
- 347-357
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2809196018
- Cited by
- 264
- References
- 29
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease. https://app.cochat.ai/papers/10.1111/apt.14853
- The paper
- Rieder, F., Bettenworth, D., Ma, C., Parker, C. E., Williamson, L. A., Nelson, S. A., van Assche, G., Di Sabatino, A., Bouhnik, Y., Stidham, R. W., Dignass, A., Rogler, G., Taylor, S. A., Stoker, J., Rimola, J., Baker, M. E., Fletcher, J. G., Panes, J., Sandborn, W. J., . . . Jairath, V. (2018). An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14853
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
